Replies to post #113985 on Biotech Values

[biomaven0]

No, the IBS market is substantial. The drug is expensive, so reimbursement for off-label use is likely very difficult, so getting the label indication will indeed be significant.

The NEJM article will be important in building sales in IBS over the long term.

Sort of stock big pharma could easily munch.

Peter